MDAI
Spectral AICNasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-22
Current thesis
If FDA De Novo arrives and UK commercialization begins to show real sales traction, the stock could re-rate sharply from a sub-$50 million market cap because the current valuation still reflects heavy skepticism around commercialization timing.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Additional capital may be needed sooner than expected, creating dilution and financing overhang.
Momentum
72
Value
37
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.80 · Bull $3.20 · Bear $0.90
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $6.25
Why
Momentum72 · Δ7d -
Value37 · Δ7d +0.0
Sentiment62 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
72
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
37
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.1
Sentiment
62
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 72.1 / Value 36.5 / Sentiment 61.5
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$53.15M
Beta
0.94
Shares Out
31.82M
P/E (TTM) · Derived
-5.8
P/S (TTM)
2.11
P/FCF (TTM) · Derived
-3.90
Rev YoY
-40.5%
EPS YoY
-196.4%
Gross Margin
+44.7%
Op Margin
-32.2%
Net Debt
-$5.3M
Current Ratio
0.75
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology